

Sarah Batson, Dean Rea, Vilmos
Fülöp and David I. Roper*Department of Biological Sciences, University of
Warwick, Coventry CV4 7AL, EnglandCorrespondence e-mail:
david.roper@warwick.ac.uk

Received 26 November 2009

Accepted 1 February 2010

Crystallization and preliminary X-ray analysis of a D-alanyl-D-alanine ligase (EcDdlB) from *Escherichia coli*


A recombinant form of *Escherichia coli* DdlB (EcDdlB) has been prepared and cocrystallized with ADP and D-alanyl-D-alanine to represent the ternary complex of EcDdlB. Furthermore, EcDdlB has been cocrystallized under the same conditions with the ligands ATP and D-alanyl-D-alanine, representing the product-inhibited complex. The crystals belonged to space group $P2_12_12_1$, with unit-cell parameters $a = 53.0$, $b = 97.6$, $c = 109.5$ Å and $a = 51.2$, $b = 97.8$, $c = 110.1$ Å, respectively, and both contained two molecules in the asymmetric unit. Complete data sets were collected to 1.5 and 1.4 Å resolution, respectively, from single crystals under cryogenic conditions using synchrotron radiation.

1. Introduction

Peptidoglycan is a specific dynamic structure which constitutes a vital component of the bacterial cell wall (Vollmer *et al.*, 2008). The biosynthesis of peptidoglycan occurs in three distinct phases at different locations and stages of the cell cycle. The initial cytoplasmic stage sequentially assembles the peptidoglycan intermediates prior to their translocation across the cell membrane. At the bacterial exoplasmic surface subsequent transpeptidation and transglycosylation reactions occur to produce mature cross-linked chains of peptidoglycan. D-Alanyl-D-alanine ligase (Ddl) is a cytoplasmic enzyme specific to peptidoglycan synthesis; it provides the D-alanyl-D-alanine dipeptide substrate for MurF in the initial cytoplasmic phase of biosynthesis (Neuhaus, 1962). The D-alanyl-D-alanine dipeptide is a central component of the biosynthetic pathway and is produced by Ddl in an ATP-dependent reaction mechanism which proceeds in two steps (Parsons *et al.*, 1988; Mullins *et al.*, 1990). Although D-cycloserine has long been known to inhibit Ddls and alanine racemase, problems arising from the toxicity of the drug mean that its administration is restricted (Neuhaus & Lynch, 1962) apart from the treatment of *Mycobacterium tuberculosis* infections. Nevertheless, Ddls present an attractive target for chemotherapeutic intervention because of their essential and universal role in bacterial cell-wall formation.

The enterococcal homologue of EcDdlB, D-alanyl-D-alanine ligase (VanA), functions in the mechanism of vancomycin resistance and also represents a novel target in the reversal of vancomycin resistance (Bugg *et al.*, 1991). Therefore, the study of these enzymes is of prime interest in the search for new antimicrobials, particularly by rational drug-design methods. In order to elucidate the structural and chemical basis of enzyme activity, the crystal structures of Ddl from *Escherichia coli* (Fan *et al.*, 1994), *Staphylococcus aureus* (Liu *et al.*, 2006), *Thermus caldophilus* (Lee *et al.*, 2006), *Helicobacter pylori* (Wu *et al.*, 2008) and *T. thermophilus* HB8 (Kitamura *et al.*, 2009) have been reported. Additionally, the crystal structures of D-alanyl-D-lactate ligases from *Enterococcus faecium* (Roper *et al.*, 2000) and *Leuconostoc mesenteroides* (Kuzin *et al.*, 2000) have been reported.

EcDdlB represents one of the two isoforms of Ddl that exist in *E. coli* and that have been kinetically characterized previously (Zawadzke *et al.*, 1991). Currently, two wild-type structures of *E. coli* EcDdlB have been solved by X-ray crystallography in addition to a mutant form, Y216F EcDdlB. The first of these represented the first

© 2010 International Union of Crystallography
All rights reserved

structure of a Ddl to be solved (Fan *et al.*, 1994) and is in complex with ADP and a phosphophosphinate transition-state analogue. The structure identified several active-site residues and formed the basis for much of the subsequent work in the field of the Ddls (Shi & Walsh, 1995; Park *et al.*, 1996; Lessard *et al.*, 1999; Prevost *et al.*, 2000). The subsequent structures of wild-type EcDdlB and Y216F EcDdlB with phosphonate and phosphinate intermediates revealed no major conformational changes in comparison to the first published structure (Fan *et al.*, 1997): both are in complex with a transition-state intermediate and exist in closed enzyme conformations. Here, we report the crystallization and preliminary characterization of EcDdlB in complex with ATP and D-alanyl-D-alanine and in complex with ADP and D-alanyl-D-alanine. D-Alanyl-D-alanine acts as a substrate for the reverse reaction of ADP/P_i-dependent phosphorylation, which occurs at a V_{\max} of less than 1% of the forward reaction (Mullins *et al.*, 1990). EcDdlB has also previously been reported to display noncompetitive product inhibition (with a reported K_i of 49 μM ; Zawadzke *et al.*, 1991). This suggests that the mode of binding of D-alanyl-D-alanine to the active site is different as a substrate and as an inhibitor, forming the rationale for cocrystallization studies of EcDdlB with ATP and D-alanyl-D-alanine. Furthermore, in contrast to previously reported transition-state mimic-containing EcDdlB structures, crystallographic studies of EcDdlB containing ADP and D-alanyl-D-alanine have been performed in order to determine the true ternary complex structure of EcDdlB. Further structural information regarding EcDdlB may contribute to a greater structural understanding of EcDdlB and may contribute to the design of effective ligase inhibitors.

2. Materials and methods

2.1. Cloning, overproduction and purification of *E. coli* EcDdlB

The gene for EcDdlB was amplified by PCR and cloned into the *Nco*I and *Xho*I sites of pProEXa (Invitrogen) to produce an aminoterminal histidine-tagged protein; the tag was not removed for crystallization. Freshly transformed *E. coli* BL21(λ DE3)Star-pRosetta cells harbouring pProEX::EcDdlB were grown in 1 l Luria broth medium containing 50 $\mu\text{g ml}^{-1}$ ampicillin and 30 $\mu\text{g ml}^{-1}$ chloramphenicol. The culture was grown at 310 K to an OD₆₀₀ of 0.5, at which point isopropyl β -D-1-thiogalactopyranoside was added to a final concentration of 1 mM. After 3 h of induction at 310 K, cells were harvested by centrifugation, resuspended in 30 ml buffer A (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole) and sonicated. Cellular debris was removed by centrifugation at 20 000g for 30 min and the supernatant was applied onto a 5 ml HisTrap Fast Flow column (GE Healthcare) equilibrated with buffer A. EcDdlB was eluted with a gradient of 10–250 mM imidazole over 60 ml.

The fractions containing EcDdlB were pooled, concentrated with a Centriprep-30 concentrator and applied onto a Superdex 200 column equilibrated with 150 mM KCl, 50 mM HEPES pH 7.5 and 0.5 mM EDTA. EcDdlB was eluted with approximately 180 ml buffer. The fractions containing recombinant EcDdlB were analysed by SDS-PAGE (Fig. 1), pooled and concentrated to 12 mg ml⁻¹ using a Centriprep-30 concentrator. Enzyme activity was determined using a continuous spectrometric assay monitoring ADP release as described previously (Daub *et al.*, 1988).

2.2. Crystallization

All crystallization experiments were performed using vapour diffusion. Initial crystallization was performed using the sitting-drop vapour-diffusion method. The protein concentration used for crystallization was 12 mg ml⁻¹ in 5 mM ATP or 5 mM ADP and 50 mM

D-alanyl-D-alanine and a ratio of one volume of protein solution to one volume of precipitant solution was used throughout. Crystals were obtained in conditions from a commercially available crystal screen (Molecular Dimensions). Refinement of the Tris-HCl conditions from pH 8.5 to pH 8 using the hanging-drop vapour-diffusion method gave crystals of sufficient quality for data collection.

2.3. Data collection

Single crystals of the EcDdlB complexes were flash-cooled in liquid nitrogen using reservoir solution containing 30% glycerol as a cryoprotectant. X-ray diffraction data were collected on beamline I04 at Diamond (UK). Diffraction images were measured using an ADSC Quantum 315 CCD detector.

3. Results and discussion

The *E. coli* EcDdlB protein was purified by immobilized metal-affinity chromatography and size-exclusion chromatography to yield 10 mg purified protein from 1 l culture. SDS-PAGE analysis revealed that the preparation was free of major and minor contaminating species. The subunit molecular mass on SDS-PAGE appeared to be consistent with the calculated molecular mass of 34 533 Da. The catalytic efficiency for D-alanyl-D-alanine synthesis was found to be $477.4 \pm 0.7 \text{ min}^{-1} \text{ mM}^{-1}$, a value that is comparable to that obtained in a previous kinetic analysis of EcDdlB ($440 \text{ min}^{-1} \text{ mM}^{-1}$) in a non-histidine-tagged form (Park *et al.*, 1996).

The best crystals were obtained at 291 K using the hanging-drop method by mixing 1 μl protein solution containing 5 mM ATP or 50 mM ADP and 50 mM D-alanyl-D-alanine with 1 μl crystallization solution containing 0.2 M MgCl₂, 25% PEG 3350, 0.1 M Tris-HCl pH 8.0 and equilibrating against a 500 μl reservoir. Crystals appeared after 2 d as plates of dimensions of 0.1 \times 0.35 mm (Figs. 2 and 3). We are confident these crystals contained the ligands that were cocrystallized since EcDdlB did not crystallize under the same conditions in the apo form or with ATP, ADP or D-alanyl-D-alanine alone.




Figure 1 12% SDS-PAGE analysis of the purification of EcDdlB. Lane M_r , molecular-weight standards (kDa); lane 1, crude cell lysate; lane 2, flowthrough from immobilized metal-affinity chromatography; lane 3, peak from immobilized metal-affinity chromatography; lane 4, peak from size-exclusion chromatography.

Initial diffraction experiments were carried out at the ESRF, but complete data sets were collected to resolutions of 1.4 Å for EcDdlB-ATP-D-alanyl-D-alanine and 1.5 Å for EcDdlB-ADP-D-alanyl-D-alanine on the I04 beamline at the Diamond synchrotron (UK) using an ADSC Q315 CCD detector with an oscillation angle of 1° and a crystal-to-detector distance of 160 mm. All data were indexed, integrated and scaled using the *HKL* suite of programs (Otwinowski & Minor, 1997). Data-collection and processing statistics are shown in Table 1. For each data set, Matthews probability calculations suggested the presence of two molecules in the asymmetric unit, although a self-rotation function did not reveal the presence of a noncrystallographic rotational axis (Matthews, 1968; Kantardjieff & Rupp, 2003). A native Patterson map suggested the presence of pseudo-translation, with a high peak in the $(u, v, \frac{1}{2})$ Harker section (94σ and 31σ , corresponding to 40% and 13% of the origin-peak height, for the two data sets, respectively). Molecular-replacement solution using *Phaser* (McCoy *et al.*, 2007) with the coordinates of the Y216F EcDdlB mutant (PDB code 1i0w; Fan *et al.*, 1997) as a model subsequently revealed two molecules in the crystallographic asymmetric unit which are related to each other by a twofold rotation parallel to the z crystallographic axis for both data sets.

Models of the EcDdlB-ATP-D-alanyl-D-alanine complex and the EcDdlB-ADP-D-alanyl-D-alanine complex are currently being built and refined. We are also seeking to crystallize the protein in the apo form and in complex with inhibitors. Ultimately, these studies may




Figure 2
Photograph of EcDdlB crystals obtained in the presence of ATP and D-alanyl-D-alanine grown in 0.2 M MgCl₂, 25% PEG 3350, 0.1 M Tris-HCl pH 8.0. The approximate dimensions of the individual crystals are 0.1 × 0.35 × 0.02 mm.




Figure 3
Photograph of EcDdlB crystals obtained in the presence of ADP and D-alanyl-D-alanine grown in 0.2 M MgCl₂, 25% PEG 3350, 0.1 M Tris-HCl pH 8.0. The approximate dimensions of the individual crystals are 0.1 × 0.4 × 0.02 mm.

Table 1
Data-collection and processing statistics.

Values in parentheses are for the highest resolution shell.

	EcDdlB-ATP-D-alanyl-D-alanine	EcDdlB-ADP-D-alanyl-D-alanine
Beamline	I04, Diamond	I04, Diamond
Detector	ADSC Q315 CCD	ADSC Q315 CCD
Wavelength (Å)	0.9763	0.9763
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
Unit-cell parameters		
<i>a</i> (Å)	51.23	53.00
<i>b</i> (Å)	97.80	97.62
<i>c</i> (Å)	110.12	109.49
Molecules per ASU	2	2
Matthews coefficient (Å ³ Da ⁻¹)	2.09	2.14
Solvent content (%)	41	43
Resolution range (Å)	49–1.4 (1.45–1.4)	48–1.5 (1.55–1.5)
Total observations	648917	601481
Unique reflections	106197	91443
Average <i>I</i> / σ (<i>I</i>)	22.4 (2.1)	18.9 (2.1)
<i>R</i> _{merge} † (%)	0.069 (0.577)	0.093 (0.578)
Completeness (%)	97.1 (94.6)	99.9 (99.1)

† $R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$, where $I_i(hkl)$ is the *i*th observation of reflection *hkl* and $\langle I(hkl) \rangle$ is the mean intensity of that reflection

contribute to further understanding of the individual reaction steps of the mechanism, the activity-associated conformational changes and the rational design of specific inhibitors against Ddls.

This work was supported by a University of Warwick PhD studentship to SB and in part by MRC research grants G500643 and G0600801 and Wellcome Trust equipment grants 071998 and 068598. Equipment used in this research was obtained through the Birmingham-Warwick Science City Translational Medicine: Experimental Medicine Network of Excellence project, with support from Advantage West Midlands (AWM). Crystallographic data were collected at beamlines IO4 at Diamond Light Source, UK and at ID14.1 at the ESRF, France, and we acknowledge the support of beamline scientists Ralf Flaig (Diamond) and Matthew Bowler (ESRF).

References

- Bugg, T. D., Dutka-Malen, S., Arthur, M., Courvalin, P. & Walsh, C. T. (1991). *Biochemistry*, **30**, 2017–2021.
- Daub, E., Zawadzke, L. E., Botstein, D. & Walsh, C. T. (1988). *Biochemistry*, **27**, 3701–3708.
- Fan, C., Moews, P. C., Walsh, C. T. & Knox, J. R. (1994). *Science*, **266**, 439–443.
- Fan, C., Park, I. S., Walsh, C. T. & Knox, J. R. (1997). *Biochemistry*, **36**, 2531–2538.
- Kantardjieff, K. A. & Rupp, B. (2003). *Protein Sci.* **12**, 1865–1871.
- Kitamura, Y., Ebihara, A., Agari, Y., Shinkai, A., Hirotsu, K. & Kuramitsu, S. (2009). *Acta Cryst.* **D65**, 1098–1106.
- Kuzin, A. P., Sun, T., Jorzak-Baillass, J., Healy, V. L., Walsh, C. T. & Knox, J. R. (2000). *Structure*, **8**, 463–470.
- Lee, J. H., Na, Y., Song, H. E., Kim, D., Park, B. H., Rho, S. H., Im, Y. J., Kim, M. K., Kang, G. B., Lee, D. S. & Eom, S. H. (2006). *Proteins*, **64**, 1078–1082.
- Lessard, I. A., Healy, V. L., Park, I. S. & Walsh, C. T. (1999). *Biochemistry*, **38**, 14006–14022.
- Liu, S., Chang, J. S., Herberg, J. T., Horng, M. M., Tomich, P. K., Lin, A. H. & Marotti, K. R. (2006). *Proc. Natl Acad. Sci. USA*, **103**, 15178–15183.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Mullins, L. S., Zawadzke, L. E., Walsh, C. T. & Raushel, F. M. (1990). *J. Biol. Chem.* **265**, 8993–8998.
- Neuhaus, F. C. (1962). *J. Biol. Chem.* **237**, 778–786.
- Neuhaus, F. C. & Lynch, J. L. (1962). *Biochem. Biophys. Res. Commun.* **8**, 377–382.

- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Park, I. S., Lin, C. H. & Walsh, C. T. (1996). *Biochemistry*, **35**, 10464–10471.
- Parsons, W. H., Patchett, A. A., Bull, H. G., Schoen, W. R., Taub, D., Davidson, J., Combs, P. L., Springer, J. P., Gadebusch, H., Weissberger, B., Valiant, M. E., Mellin, T. N. & Busch, R. D. (1988). *J. Med. Chem.* **31**, 1772–1778.
- Prevost, M., Van Belle, D., Tulkens, P. M., Courvalin, P. & Van Bambeke, F. (2000). *J. Mol. Microbiol. Biotechnol.* **2**, 321–330.
- Roper, D. I., Huyton, T., Vagin, A. & Dodson, G. (2000). *Proc. Natl Acad. Sci. USA*, **97**, 8921–8925.
- Shi, Y. & Walsh, C. T. (1995). *Biochemistry*, **34**, 2768–2776.
- Vollmer, W., Blanot, D. & de Pedro, M. A. (2008). *FEMS Microbiol. Rev.* **32**, 149–167.
- Wu, D., Zhang, L., Kong, Y., Du, J., Chen, S., Chen, J., Ding, J., Jiang, H. & Shen, X. (2008). *Proteins*, **72**, 1148–1160.
- Zawadzke, L. E., Bugg, T. D. & Walsh, C. T. (1991). *Biochemistry*, **30**, 1673–1682.